AstraZeneca PLC
AZN
$89.10
$0.490.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 44.71% | 28.80% | 22.76% | 18.14% | 10.16% |
| Total Depreciation and Amortization | -2.56% | 14.57% | 13.54% | 13.50% | 12.47% |
| Total Amortization of Deferred Charges | -28.57% | -28.57% | -28.57% | -28.57% | -4.11% |
| Total Other Non-Cash Items | 179.51% | 131.48% | 131.99% | 101.25% | 52.03% |
| Change in Net Operating Assets | 27.23% | -333.26% | -117.63% | -397.67% | -187.53% |
| Cash from Operations | 33.58% | 21.00% | 34.96% | 14.65% | 9.37% |
| Capital Expenditure | -42.56% | -34.69% | -26.45% | -41.37% | -44.12% |
| Sale of Property, Plant, and Equipment | -77.78% | -79.66% | -95.00% | -58.33% | -86.36% |
| Cash Acquisitions | 66.94% | 68.77% | -97.16% | -244.13% | -254.33% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -15.29% | -18.72% | 20.94% | -34.16% | -79.53% |
| Cash from Investing | 16.92% | 20.14% | -30.38% | -96.36% | -143.39% |
| Total Debt Issued | -88.49% | -90.01% | -73.24% | 63.24% | 96.44% |
| Total Debt Repaid | 92.14% | 46.13% | -55.37% | 4.05% | -6.50% |
| Issuance of Common Stock | 11.11% | 8.33% | 14.29% | 15.15% | 20.00% |
| Repurchase of Common Stock | -527.16% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.41% | -10.62% | -10.66% | -3.30% | -3.33% |
| Other Financing Activities | 112.12% | 114.21% | 114.43% | 7.79% | 7.79% |
| Cash from Financing | -36.42% | -216.19% | -248.13% | 39.15% | 45.49% |
| Foreign Exchange rate Adjustments | 26.92% | 120.00% | 76.84% | -55.00% | 56.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,080.98% | -70.56% | -233.32% | 39.88% | -142.49% |